Slide 1: Genomic Medicine
Genomic Medicine Launching our latest R&D publication Dr. Christoph Nabholz, Head R&D Life & Health, 7 Nov 2017
Slide 2: Key facts about genomic medicine in clinical practice
Key facts about genomic medicine in clinical practice Genomic medicine in medical practice Vincent Mooser, Jacques Fellay (CHUV University Hospital, Lausanne) Dr Christoph Nabholz | Genomic Medicine | 7 Nov 2017 2
Slide 3: Rapid evolution of genetic testing technologies observed since the human genome sequence in 2003
Rapid evolution of genetic testing technologies observed since the human genome sequence in 2003 Whole Genome Whole Exome Sequencing Sequencing Gene Panels Single Gene Testing Dr Christoph Nabholz | Genomic Medicine | 7 Nov 2017 3
Slide 4: Full genome sequencing has become affordable
Full genome sequencing has become affordable Sequencing costs per genome $100'000'000 $10'000'000 $1M genome 2008 $1'000'000 $100'000 $10K genome 2011 $10'000 $1'000 $100 genome? $100 Sanger sequencing Next generation Emerging sequencing sequencing Source: NIH National Human Genome Research Institut
Slide 5: Molecular-profiling has become key to the development of personalised therapy
Molecular-profiling has become key to the development of personalised therapy Personalised medicine Disease-free Understanding of genetic variability between individuals and using such personalised information for targeted healthcare Symptomatic Source: Herbst R et al. N Engl J Med 2008; 359: 1367 D
Slide 6: Liquid biopsy is a novel cancer blood test that has the potential to revolutionize cancer care
Liquid biopsy is a novel cancer blood test that has the potential to revolutionize cancer care and provide personalized therapy guidance Liquid biopsy in Oncology Nicola Aceto (University of Basel) Dr Christoph Nabholz | Genomic Medicine | 7 Nov 2017 6
Slide 7: Liquid biopsy provides the molecular understanding of the cancer
Liquid biopsy provides the molecular understanding of the cancer and provides the hope to better manage cancer treatment through: Real-time monitoring of treatment responses and resistance to therapy Detecting cancer relapse Development of targeted therapies Stratification and therapeutic decision m
Slide 8: Used as a cancer screening tool liquid biopsy has the potential to lead to overdiagnosis
Used as a cancer screening tool liquid biopsy has the potential to lead to overdiagnosis and impact cancer products Liquid biopsy – a new blood test for cancer challenges the insurance industry Giselle Abangma, Christoph Nabholz, Florian Rechfeld, John Schoonbee (Swiss Re) Dr Christoph Nabholz | Gen
Slide 9: Heritable modification of the genome that does not change the DNA sequence
Heritable modification of the genome that does not change the DNA sequence Transgenerational epigenetic inheritance: a paradigm shift in biology and medicine Johannes Bohacek, Isabelle Mansuy (ETH and University of Zurich) Dr Christoph Nabholz | Genomic Medicine | 7 Nov 2017 9
Slide 10: Gene editing could be used to cure genetic disease but is it ethical?
Gene editing could be used to cure genetic disease but is it ethical? CRISPR – hacking the biological hard drive Thomas Wildhaber, Séverine Rion, Christoph Nabholz (Swiss Re) Dr Christoph Nabholz | Genomic Medicine | 7 Nov 2017 10
Slide 11: Human gene manipulation – Hopes and Fears
Human gene manipulation – Hopes and Fears Embryonic Stem Cell Big Hope: Big Fear: Cure of genetic diseases Designer baby Dr Christoph Nabholz | Genomic Medicine | 7 Nov 2017
Slide 12: Therapeutic approaches
Therapeutic approaches Gene therapy Cell therapy Reprogramming of stem cells Change gene defect to replace defective tissue Treatment Embryonic Adult stem Embryonic of affected therapy cells stem cells tissue Dr Christoph Nabholz | Genomic Medicine | 7 Nov 2017
Slide 13: International law – Embryonic stem cell research
International law – Embryonic stem cell research Country Research Country Research permitted / prohibited permitted / prohibited Australia Japan Canada Netherland Denmark Norway China Poland France highly restricted Singapore no specific law Germany South Korea Iceland Spai
Slide 14: Insurance impact
Insurance impact Casualty Life & Health • Biohacking • New promising high tech – Modified organisms may escape therapies and lead to ecosystem impact – Small patient groups with very high cost to health care system • Genetic Modified Organism – Regulatory restriction may lead • Risk of developing di
Slide 15: Dr Christoph Nabholz | Genomic Medicine | 7 Nov 2017
Dr Christoph Nabholz | Genomic Medicine | 7 Nov 2017 15
Slide 16: Legal notice
Legal notice ©2017 Swiss Re. All rights reserved. You are not permitted to create any modifications or derivative works of this presentation or to use it for commercial or other public purposes without the prior written permission of Swiss Re. The information and opinions contained in the presentati